This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toyoda, H. Articles by Cello, J. Search for Related Content PubMed PubMed Citation Articles by Toyoda, H. Articles by Cello, J.

Oncolytic Treatment and Cure of Neuroblastoma by a Novel Attenuated Poliovirus in a Novel Poliovirus-Susceptible Animal Model

Department of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, New York

Requests for reprints: Eckard Wimmer, Department of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, NY 11794-5222. E-mail: ewimmer{at}ms.cc.sunysb.edu.

Neuroblastoma is one of the most common solid tumors in children. Treatment is of limited utility for high-risk neuroblastoma and prognosis is poor. Resistance of neuroblastoma to conventional therapies has prompted us to search for a novel therapeutic approach based on genetically modified polioviruses. Poliovirus targets motor neurons leading to irreversible paralysis. Neurovirulence can be attenuated by point mutations or by exchange of genetic elements between different picornaviruses. We have developed a novel and stable attenuated poliovirus, replicating in neuroblastoma cells, by engineering an indigenous replication element (cre), copied from a genome-internal site, into the 5'-nontranslated genomic region (mono-crePV). An additional host range mutation (A₁₃₃G) conferred replication in mouse neuroblastoma cells (Neuro-2a^CD155) expressing CD155, the poliovirus receptor. Crossing immunocompetent transgenic mice susceptible to poliovirus (CD155 tg mice) with A/J mice generated CD155 tgA/J mice, which we immunized against poliovirus. Neuro-2a^CD155 cells were then transplanted into these animals, leading to lethal tumors. Despite preexisting high titers of anti-poliovirus antibodies, established lethal s.c. Neuro-2a^CD155 tumors in CD155 tgA/J mice were eliminated by intratumoral administrations of A₁₃₃Gmono-crePV. No signs of paralysis were observed. Interestingly, no tumor growth was observed in mice cured of neuroblastoma that were reinoculated s.c. with Neuro-2a^CD155. This result indicates that the destruction of neuroblastoma cells by A₁₃₃Gmono-crePV may lead to a robust antitumor immune response. We suggest that our novel attenuated oncolytic poliovirus is a promising candidate for effective oncolytic treatment of human neuroblastoma or other cancer even in the presence of present or induced antipolio immunity. [Cancer Res 2007;67(6):2857–64]

This article has been cited by other articles:

				J. R. Coleman, D. Papamichail, S. Skiena, B. Futcher, E. Wimmer, and S. Mueller Virus Attenuation by Genome-Scale Changes in Codon Pair Bias Science, June 27, 2008; 320(5884): 1784 - 1787. [Abstract] [Full Text] [PDF]

				L. M. Hales, N. J. Knowles, P. S. Reddy, L. Xu, C. Hay, and P. L. Hallenbeck Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus J. Gen. Virol., May 1, 2008; 89(5): 1265 - 1275. [Abstract] [Full Text] [PDF]

				H. Toyoda, D. Franco, K. Fujita, A. V. Paul, and E. Wimmer Replication of Poliovirus Requires Binding of the Poly(rC) Binding Protein to the Cloverleaf as Well as to the Adjacent C-Rich Spacer Sequence between the Cloverleaf and the Internal Ribosomal Entry Site J. Virol., September 15, 2007; 81(18): 10017 - 10028. [Abstract] [Full Text] [PDF]